Capricor Therapeutics, Inc.
CAPR- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001133869
No open-market purchases or sales by Capricor Therapeutics, Inc. insiders were filed in the last 90 days; 169 institutions reported holding it in 13F filings for Q2 2026, worth $941.6M in total; no superinvestor holds it.
Q2 2021 vs. Q1 2021
How the institutions holding Capricor Therapeutics, Inc. changed between Q1 2021 and Q2 2021.
All holders in Q2 2021All holders in Q1 2021
| Measure | Q1 2021 | Q2 2021 | Change |
|---|---|---|---|
| Holders | 30 | 31 | +1 |
| Shares | 4.38M | 3.53M | −856.1K (−19.5%) |
| Value | $20.5M | $18.1M | −$2.42M (−11.8%) |
New holders (4)
Institutions that held Capricor Therapeutics, Inc. at the end of Q2 2021 but not at the end of Q1 2021.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| State Street Corp | 71,748 | $368.0K | 0.00% |
| Deutsche Bank AG | 145 | $1.00K | 0.00% |
| JPMorgan Chase & Co | 77 | $0 | 0.00% |
| Bank of America Corp | 10 | $0 | 0.00% |
Sold out (3)
Institutions that held Capricor Therapeutics, Inc. at the end of Q1 2021 and filed for Q2 2021 without it.
| Institution | Shares, Q1 2021 | Value, Q1 2021 |
|---|---|---|
| Trellus Management Company, LLC | 270,000 | $1.26M |
| M Holdings Securities, Inc. | 20,000 | $94.0K |
| Brown Brothers Harriman & Co | 5,112 | $24.0K |